imaradenant + spartalizumab

This combination consists of **imaradenant**, a potent and selective oral small molecule antagonist of the adenosine A2A receptor, and **spartalizumab**, a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1). Imaradenant is hypothesized to reduce immunosuppression in the tumor microenvironment and enhance anti-tumor immune responses[1][5]. Spartalizumab blocks the PD-1 receptor to prevent inhibitory signaling in T cells, promoting immune-mediated tumor cell killing[2][3]. Both agents are developed for immuno-oncology; their combination aims to augment the immune response against tumors.